The US Food and Drug Administration (FDA) has granted Neuros Medical investigational device exemption approval to initiate a pilot clinical trial to investigate its patented high-frequency electrical nerve-block technology, designed for the acute treatment of pain in the residual limbs of amputees.

The technology will eliminate chronic pain in a number of applications, such as amputation pain, chronic post-surgical pain, chronic migraine and trigeminal neuralgia.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The approval is supported by the first-in-man feasibility study, in which four out of five patients reported improvements in pain, reducing pain scores to zero.

Neuros Medical president and CEO Jon Snyder said the company will further commence the pilot study to provide long term safety and efficacy data of electrical nerve block technology in a larger set of patients.

Medical Device Network Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Medical Device Network Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now